Scotia Capital’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.7M | Sell |
211,351
-19,426
| -8% | -$3.75M | 0.17% | 84 |
|
|
2025
Q4 | $42.4M | Buy |
230,777
+6,258
| +3% | +$1.1M | 0.17% | 89 |
|
|
2025
Q3 | $34.5M | Buy |
224,519
+17,876
| +9% | +$2.71M | 0.15% | 95 |
|
|
2025
Q2 | $28.9M | Buy |
206,643
+54,900
| +36% | +$7.69M | 0.14% | 95 |
|
|
2025
Q1 | $22.3M | Buy |
151,743
+35,844
| +31% | +$5.19M | 0.12% | 107 |
|
|
2024
Q4 | $15.2M | Sell |
115,899
-90,872
| -44% | -$12.7M | 0.08% | 136 |
|
|
2024
Q3 | $32.2M | Buy |
206,771
+19,893
| +11% | +$3.21M | 0.17% | 86 |
|
|
2024
Q2 | $29.1M | Buy |
186,878
+36,081
| +24% | +$5.43M | 0.17% | 88 |
|
|
2024
Q1 | $20.4M | Buy |
150,797
+69,170
| +85% | +$9.16M | 0.12% | 107 |
|
|
2023
Q4 | $11M | Buy |
81,627
+13,319
| +19% | +$1.73M | 0.07% | 155 |
|
|
2023
Q3 | $9.25M | Buy |
68,308
+6,814
| +11% | +$931K | 0.07% | 160 |
|
|
2023
Q2 | $8.8M | Buy |
61,494
+5,548
| +10% | +$816K | 0.06% | 165 |
|
|
2023
Q1 | $7.77M | Sell |
55,946
-2,005
| -3% | -$270K | 0.06% | 178 |
|
|
2022
Q4 | $7.86M | Sell |
57,951
-3,565
| -6% | -$447K | 0.06% | 170 |
|
|
2022
Q3 | $6.75M | Buy |
61,516
+10,420
| +20% | +$1.32M | 0.05% | 185 |
|
|
2022
Q2 | $6.75M | Buy |
51,096
+6,123
| +14% | +$803K | 0.05% | 191 |
|
|
2022
Q1 | $5.97M | Buy |
44,973
+4,486
| +11% | +$538K | 0.04% | 225 |
|
|
2021
Q4 | $4.72M | Buy |
40,487
+9,107
| +29% | +$1.07M | 0.03% | 268 |
|
|
2021
Q3 | $3.77M | Buy |
31,380
+24,375
| +348% | +$2.84M | 0.03% | 283 |
|
|
2021
Q2 | $839K | Sell |
7,005
-2,070
| -23% | -$227K | 0.01% | 542 |
|
|
2021
Q1 | $902K | Sell |
9,075
-1,337
| -13% | -$134K | 0.01% | 511 |
|
|
2020
Q4 | $1.04M | Buy |
10,412
+968
| +10% | +$103K | 0.01% | 435 |
|
|
2020
Q3 | $1.03M | Buy |
+9,444
| New | +$1.05M | 0.01% | 391 |
|
|
2020
Q2 | – | Sell |
-5,631
| Closed | -$503K | – | 645 |
|
|
2020
Q1 | $503K | Buy |
5,631
+547
| +11% | +$51.5K | 0.01% | 435 |
|
|
2019
Q4 | $507K | Buy |
5,084
+100
| +2% | +$9.41K | 0.01% | 510 |
|
|
2019
Q3 | $444K | Sell |
4,984
-67
| -1% | -$5.81K | 0.01% | 543 |
|
|
2019
Q2 | $417K | Buy |
5,051
+67
| +1% | +$5.25K | 0.01% | 549 |
|
|
2019
Q1 | $403K | Buy |
4,984
+2,131
| +75% | +$168K | 0.01% | 532 |
|
|
2018
Q4 | $217K | Sell |
2,853
-390
| -12% | -$30.5K | ﹤0.01% | 591 |
|
|
2018
Q3 | $257K | Buy |
3,243
+335
| +12% | +$25.3K | ﹤0.01% | 637 |
|
|
2018
Q2 | $201K | Hold |
2,908
| – | – | ﹤0.01% | 629 |
|
|
2018
Q1 | $203K | Buy |
+2,908
| New | +$201K | ﹤0.01% | 655 |
|
Other funds holding AZN
IA
VCM
VAM
Scotia Capital's AZN Position: Q1 2026 in Review
Scotia Capital reduced its AstraZeneca (AZN) stake by 8.4% in Q1 2026, selling an estimated $3.75M and leaving 211,351 shares worth $41.7M. The position accounts for 0.17% of the portfolio, ranked #84.
Scotia Capital first reported a position in AZN in Q1 2018 and has held it in 32 quarters since. The position peaked at $42.4M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Scotia Capital held 211,351 shares of AstraZeneca worth $41.7M as of Q1 2026.
- Scotia Capital sold 19,426 AstraZeneca shares in Q1 2026, an estimated $3.75M.
- AstraZeneca made up 0.17% of Scotia Capital's portfolio in Q1 2026, its #84 holding.
- Scotia Capital first reported a position in AstraZeneca in Q1 2018 and has held it in 32 quarters since.
- Scotia Capital's AstraZeneca position peaked at $42.4M in Q4 2025.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.